Hypersexuality with Antiparkinsonian Therapy
- 1 October 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 12 (5), 375-383
- https://doi.org/10.1097/00002826-198910000-00002
Abstract
Thirteen parkinsonian patients drawn from two large parkinsonism clinics experienced hypersexuality as a consequence of anti-parkinsonian therapy. The cases include only those whose sexual behavior on treatment became a concern to the patient's family or a social agency. The majority of patients were men and had a relatively early onset of parkinsonian symptomatology. There was no relation between functional improvement and increased sexuality. Most patients showed some element of dose dependency between antiparkinsonian drugs and the hypersexual behavior. Prior sexual profile included from no sexual outlet to hypersexuality. Neither the prior history of psychiatric illness nor brain damage predisposed to such response on treatment, and in most patients, it was not a part of hypomania or a more diffuse psychiatric disturbance. We propose that hypersexuality on antiparkinsonian drugs is consequent to inhibition of prolactin secretion.This publication has 6 references indexed in Scilit:
- Hypersexuality or altered sexual preference following brain injury.Journal of Neurology, Neurosurgery & Psychiatry, 1986
- HYPERPROLACTINAEMIA IN MEN?RESPONSE TO BROMOCRIPTINE THERAPYThe Lancet, 1982
- Prolactin secretion in Parkinson diseaseNeurology, 1981
- Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapyNeurology, 1979
- Prolactin-Secreting Tumors and Hypogonadism in 22 MenNew England Journal of Medicine, 1978
- BROMOCRIPTINE TREATMENT OF MALES WITH PITUITARY TUMOURS, HYPERPROLACTINAEMIA, AND HYPOGONADISMClinical Endocrinology, 1978